论文部分内容阅读
这项新型戒烟技术使用纳米颗粒,引发免疫系统对尼古丁分子做出反应。一家波士顿创业公司正寻求非正统的方式,来帮助吸烟者戒烟——该公司试图制造全球首例成功的尼古丁疫苗。这家名为Selecta Biosciences的公司由麻省理工学院的工程师罗伯特·兰格(Robert Langer)与哈佛大学的两位免疫学家乌尔里希·冯·安德里安(Ulrichvon Andrian)和奥米德·法罗萨德(Omid Farokhzad)共同创立。公司的目标是通过诱发可持续数年的免疫反应,使吸烟者不再对烟草上瘾。虽然尼古丁不是一种病毒,但兰格及其同事认为,可以采用与
The new smoking cessation technology uses nanoparticles to trigger the immune system to respond to nicotine molecules. A Boston startup is looking for an unorthodox way to help smokers quit smoking - the company is trying to make the world’s first successful nicotine vaccine. The company, Selecta Biosciences, is run by Robert Langer, a Massachusetts Institute of Technology engineer with two immunologists at Harvard University, Ulrich Von Andrian, · Omid Farokhzad co-founded. The company’s goal is to make smokers no longer addicted to tobacco by inducing immune responses that persist for years. Although nicotine is not a virus, Lange and his colleagues think that it can be used with